

Special Issue

Multimodal Interdisciplinary Approach of Tumor Vasculogenesis and Angiogenesis in Oncology

Message from the Guest Editor

The observation of tumor vasculature dates back to ancient times. The main topics are as follows:

- Tumor endothelial cells heterogeneity and its impact on tumor angiogenesis and vasculogenesis.
- Molecular characterization of cells initiating tumor vasculogenesis.
- New innovative experimental models for the study of tumor angiogenesis and vasculogenesis.
- Chemotherapy and radiotherapy as friends or foes of tumor angiogenesis and vasculogenesis.
- Malignant cells involvement in tumor vasculogenesis.
- Tumor stroma immune microenvironment and its modulation related to tumor angiogenesis and vasculogenesis.
- New radiologic research techniques for in vivo study of tumor angiogenesis and vasculogenesis and for targeting tumor vessels.
- Nanotechnology, tumor angiogenesis and vasculogenesis.
- Artificial intelligence, tumor vasculogenesis and angiogenesis.
- Pathologist role in the assessment of tumor angiogenesis and vasculogenesis by conventional immunohistochemistry and digital image analysis and its impact on initial preliminary diagnosis.

Guest Editor

Dr. Anca-Maria Cimpan

Department of Microscopic Morphology/Histology, Angiogenesis Research Center, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/177211

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).